A5045927706- Melanoma and MAPK Pathways
- Renal cell carcinoma treatment
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Cutaneous Melanoma Detection and Management
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Click Chemistry and Applications
- Computational Drug Discovery Methods
- Redox biology and oxidative stress
- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- Synthesis of Tetrazole Derivatives
- Connexins and lens biology
- Hepatocellular Carcinoma Treatment and Prognosis
- Oral Health Pathology and Treatment
Novartis (Switzerland)
2022-2023
Tris Pharma (United States)
2021-2023
Novartis (United States)
2016-2022
Beijing Institute of Big Data Research
2016
Medical University of South Carolina
2012-2014
Covance (United States)
2013
University of California, Riverside
2009-2010
Bose Institute
1939
Abstract BACKGROUND The peroxiredoxins (PRDXs) are emerging as regulators of antioxidant defense, apoptosis, and therapy resistance in cancer. Because their significance prostate cancer (PCa) is unclear, we investigated expression clinical associations PCa. METHODS Transcript PRDX1–6 PCa was evaluated gene microarray datasets, whereas protein by immunoblotting cell lines, immunohistochemistry (IHC) tissue microarrays (TMAs) containing tumor (n = 80) control 17) tissues. PRDX3 also analyzed...
Oxidative stress-modulated signaling pathways have been implicated in carcinogenesis and therapy resistance. The lens epithelium derived growth factor p75 (LEDGF/p75) is a transcription co-activator that promotes resistance to stress-induced cell death. This protein has inflammatory autoimmune conditions, HIV-AIDS, cancer. Although LEDGF/p75 emerging as stress survival oncoprotein, there scarce information on its expression human tumors. present study was performed evaluate comprehensive...
Abstract Purpose: PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between exposure (Ctrough) was evaluated. Patients Methods: Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early Ctrough) 250 16 20 (late Ctrough). Pazopanib pharmacokinetic (PK) data analyzed via population model approach. Relationship Ctrough dose intensity...
BackgroundCOMBI-AD demonstrated long-term benefit of adjuvant dabrafenib plus trametinib in patients with resected stage III BRAF V600E/K–mutant melanoma; however, 9% permanently discontinued therapy due to pyrexia. COMBI-APlus evaluated whether an adapted pyrexia management algorithm reduces high-grade and pyrexia-related adverse outcomes.MethodsCOMBI-APlus is open-label, phase IIIb trial evaluating high-risk melanoma treated up 12 months trametinib. Both drugs were interrupted for...
Prostate cancer (PCa) mortality is driven by highly aggressive tumors characterized metastasis and resistance to therapy, this aggressiveness mediated numerous factors, including activation of stress survival pathways in the pro-inflammatory tumor microenvironment. LEDGF/p75, also known as DFS70 autoantigen, a transcription co-activator implicated cancer, HIV-AIDS, autoimmunity. This protein targeted autoantibodies certain subsets patients with PCa inflammatory conditions, well some...
Abstract Because of high relapse rates with rituximab combinations, there is an unmet need for new therapeutic agents treatment indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular (FL). In previous trials, ofatumumab in combination chemotherapy showed good results relapsed/refractory FL pretreated rituximab. This phase 3 trial evaluated the efficacy and safety single-agent vs rituximab-sensitive relapsed that at least 6 months after completing last prior a rituximab-containing regimen....
BackgroundDabrafenib plus trametinib has demonstrated clinical benefit across multiple BRAF-mutant tumours, leading to approval for resected stage III and metastatic melanoma, non–small-cell lung cancer (NSCLC) anaplastic thyroid cancer. Pyrexia is a common adverse event in patients treated with dabrafenib trametinib. Here, we characterise the incidence, patterns management of pyrexia receiving trials.MethodsPatients (N = 1076) included analysis received following trials: phase II...
Abstract Purpose: This study aimed to identify baseline clinical features associated with the outcomes of patients enrolled in COMBI-MB phase II dabrafenib and trametinib treatment V600 BRAF-mutant metastatic melanoma brain metastases (MBM). Exploratory biomarker analysis was also conducted as part synergistic COMBI-BRV trial (BRV116521), molecular immunologic changes MBMs extracranial (ECM). Patients Methods: Post hoc performed for (n = 125) COMBI-MB. Analyses were intracranial response...
We report the final analysis of PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL complete or partial remission after second- third-line treatment were randomized 1:1 to (300 mg first week, followed by 1000 every 8 weeks for up 2 years) observation. Median follow-up duration was 40.9 months. progression-free survival 34.2 and 16.9 months observation arms, respectively, (hazard ratio, 0.55 [95% confidence interval,...
The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with BRAF V600–mutant metastatic melanoma. However, real-world data characterizing benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study unresectable or melanoma treated dab monotherapy and/or tram therapy as part of the Named Patient Program Individual Program. Overall, 509 were enrolled. Patients categorized into three groups based on...
9525 Background: The long-term benefit of adjuvant dab + tram in pts with resected stage III BRAF V600E/K–mutant melanoma was demonstrated COMBI-AD where AEs led to permanent discontinuation 26% pts, most often due pyrexia (9%). COMBI-APlus trial (NCT03551626) is designed evaluate whether an adapted management algorithm could reduce high-grade and other pyrexia-related adverse outcomes, such as treatment cessation hospitalization. Methods: open-label, Phase IIIb evaluating high-risk treated...
4564 Background: PROTECT was a Phase 3 randomized placebo-controlled study to evaluate pazopanib efficacy and safety as adjuvant RCC treatment. The starting dose 800 mg daily, which reduced 600 in an attempt improve tolerability. Pazopanib trough concentrations (Ctrough) were collected from 358 patients at the 600-mg two timepoints (Week 3/ 5 Week 16/20). This analysis characterized relationship between Ctrough endpoints. Methods: disease-free survival (DFS) explored by Cox regression...
TPS8590 Background: Neoadjuvant therapy is the earliest opportunity to eliminate micrometastatic disease. Emerging data suggest that neoadjuvant in non-small cell lung cancer (NSCLC) can elicit major pathological responses (MPRs) translate into prolonged survival outcomes, serving as an early surrogate for efficacy. Adjuvant improve overall and disease-free (DFS) patients with completely resected NSCLC. DFS observed osimertinib early-stage EGFR-mutated tumors supports evaluation of other...
Smokeless tobacco use in the form of betel quid is common Western Pacific Region, and yet few studies have determined nicotine delivery this habit. During a validation substudy, we randomly sampled 201 adults from rural province Cambodia nonparametric (bootstrapped) confidence intervals (CIs) for salivary cotinine levels users. We found that daily among women (95% CI = 218.6-350.0 ng/mL) were (1) similar to cigarette smoking men 240.2-317.1 (2) significantly higher than 71.8-202.7 ng/mL)....
9523 Background: Treatment with BRAF+/-MEK inhibition (BRAF+/-MEKi) has revolutionized treatment in melanoma and other cancers, but resistance is common innovative strategies are needed. Sexual dimorphism response to BRAF+/-MEKi have been noted, mechanisms behind this poorly understood hormonal modulation not well-studied setting. Methods: We examined outcomes by sex five clinical cohorts of patients (pts) (total n = 792, 362 female, 430 male) BRAF-mutated who were treated BRAF/MEKi either...
9563 Background: DMFS is an important endpoint for patients with stage III cutaneous melanoma, as delaying or preventing systemic disease associated improved clinical and patient-reported outcomes. Prior results from the phase 3 COMBI-AD trial (NCT01682083) showed 5-year rates of 65% adjuvant D + T vs 54% placebo (PBO; hazard ratio [HR] = 0.55; 95% CI: 0.44-0.70). An analysis by AJCC-7 stages IIIA-C suggested a similar benefit PBO regardless (Dummer R et al. N Engl J Med. 2020). Here, we...
Orforglipron (OFG), an oral, non-peptide GLP-1 receptor agonist, demonstrated significantly greater glycemic control and weight loss at doses ≥12 mg vs placebo (PBO) or dulaglutide (DU) 1.5 in a 26-week phase 2 study of adults with type diabetes (T2D) (Table). These exploratory analyses investigated mechanisms by which OFG improved T2D analyzing biomarkers. Participants (mean age, 58.9 years; baseline HbA1c, 8.1%; weight, 100.3 kg) treated diet exercise, with/without metformin, were...
This is the age of big data we are living in.Everything doing these recorded somewhere and eventually that became a for most organizations in today's world.The impact abundance affecting all fields including science business positive way.The whole research world drifting toward data-driven discovery or decision making.